Acura Pharmaceuticals (ACUR) 10-K 29 Feb 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	786,947
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 27
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,833,801

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 2,485	$ 774
Marketable securities (Note 4)	10,837	11,322
Accounts receivable, net of allowances of $91 and $5	83	76
Accrued investment income	37	66
Inventories, net (Note 5)	276	304
Prepaid expenses and other current assets	417	471
Other current deferred assets	0	218
Total current assets	14,135	13,231
Property, plant and equipment, net (Note 6)	1,013	957
Intangible asset, net of accumulated amortization of $362 and $155 (Note 3)	1,638	1,845
Other assets	175	0
Total assets	16,961	16,033
Current liabilities:
Accounts payable	110	217
Accrued expenses (Note 7)	564	568
Accrued interest	0	70
Other current liabilities	45	26
Sales returns liability	205	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 8)	2,320	1,758
Total current liabilities	3,244	2,992
Long-term debt, net of debt discount of $193 and $281 and debt issuance costs of $97 and $162 (Note 8)	5,430	7,799
Long-term portion of accrued interest	387	190
Total liabilities	$ 9,061	$ 10,981
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 11,801 and 9,770 shares issued and outstanding at 2015 and 2014, respectively	$ 118	$ 98
Additional paid-in capital	375,157	367,288
Accumulated deficit	(367,310)	(362,321)
Accumulated other comprehensive loss	(65)	(13)
Total stockholders' equity	7,900	5,052
Total liabilities and stockholders' equity	$ 16,961	$ 16,033

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts receivable, net of allowances	$ 91	$ 5
Finite-lived intangible assets accumulated amortization	362	155
Long-term debt, net of debt discount	193	281
Debt Instrument Issuance Cost	$ 97	$ 162
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,801	9,770
Common stock, shares outstanding	11,801	9,770

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Revenues:
License fee revenue	$ 5,250	$ 500
Milestone revenue	2,500	0
Collaboration revenue	170	0
Royalty revenue	5	4
Product sales, net	662	247
Total revenues, net	8,587	751
Operating expenses:
Cost of sales (excluding inventory write-down)	656	227
Inventory write-down (Note 5)	330	201
Research and development	2,608	4,582
Selling, marketing, general and administrative	8,994	7,940
Total operating expenses	12,588	12,950
Operating loss	(4,001)	(12,199)
Non-Operating income (expense):
Investment income	166	198
Interest expense (Note 8)	(1,157)	(1,212)
Other income	3	4
Total other expense, net	(988)	(1,010)
Loss before income taxes	(4,989)	(13,209)
Provision for income taxes	0	0
Net loss	(4,989)	(13,209)
Other comprehensive loss:
Unrealized losses on marketable securities	(52)	(32)
Total other comprehensive loss	(52)	(32)
Comprehensive loss	$ (5,041)	$ (13,241)
Loss per share:
Basic	$ (0.46)	$ (1.35)
Diluted	$ (0.46)	$ (1.35)
Weighted average shares outstanding:
Basic	10,796	9,779
Diluted	10,796	9,779

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Restricted Stock Units (RSUs)	Cashless	Common Stock	Common StockRestricted Stock Units (RSUs)	Common StockCashless	Additional paid-in capital	Additional paid-in capitalRestricted Stock Units (RSUs)	Additional paid-in capitalCashless	Accumulated deficit	Accumulated deficitRestricted Stock Units (RSUs)	Accumulated deficitCashless	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss)Restricted Stock Units (RSUs)	Accumulated Other Comprehensive Income (Loss)Cashless
Balance at Dec. 31, 2013	$ 17,923			$ 97			$ 366,919			$ (349,112)			$ 19
Balance (in shares) at Dec. 31, 2013				9,665
Net loss	(13,209)			$ 0			0			(13,209)			0
Other comprehensive loss	(32)			0			0			0			(32)
Share-based compensation	890			0			890			0			0
Net distribution of common stock pursuant to restricted stock unit award plan	1			$ 2			(1)			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				165
Common shares withheld for withholding taxes		$ (525)	$ (4)		$ (1)	$ 0		$ (524)	$ (4)		$ 0	$ 0		$ 0	$ 0
Common shares withheld for withholding taxes (in shares)					(63)	0
Issuance of common stock	0			$ 0			0			0			0
Issuance of common stock (in shares)				2
Issuance of common stock for exercise of stock options	8			$ 0			8			0			0
Issuance of common stock for exercise of stock options (in shares)				1
Balance at Dec. 31, 2014	5,052			$ 98			367,288			(362,321)			(13)
Balance (in shares) at Dec. 31, 2014				9,770
Net loss	(4,989)			$ 0			0			(4,989)			0
Other comprehensive loss	(52)			0			0			0			(52)
Share-based compensation	606			0			606			0			0
Net distribution of common stock pursuant to restricted stock unit award plan	0			$ 0			0			0			0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)				19
Modification to warrants issued with promissory notes	33			$ 0			33			0			0
Issuance of common stock	7,033			$ 20			7,013			0			0
Issuance of common stock (in shares)				1,958
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217			$ 0			217			0			0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)				54
Balance at Dec. 31, 2015	$ 7,900			$ 118			$ 375,157			$ (367,310)			$ (65)
Balance (in shares) at Dec. 31, 2015				11,801

CONSOLIDATED STATEMENTS OF STO6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Direct Offering [Member]
Net offering costs	$ 603
Market Offering [Member]
Net offering costs	$ 8

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash Flows from Operating Activities:
Net loss	$ (4,989)	$ (13,209)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	125	119
Provision to reduce inventory to net realizable value	330	201
Provision for sales returns	267	0
Share-based compensation	606	890
Amortization of debt discount and debt issuance costs	186	188
Amortization of bond premium in marketable securities	127	250
Amortization of intangible asset	207	155
Gain on sales of marketable securities	(3)	(4)
Loss on disposals of property, plant and equipment	19	0
Changes in assets and liabilities:
Accounts receivable, net	(69)	118
Accrued investment income	29	54
Inventories	(302)	(254)
Prepaid expenses and other current assets	54	158
Other current deferred assets	218	(32)
Other assets	(175)	5
Accounts payable	(107)	(57)
Accrued expenses	(4)	27
Deferred revenue	(353)	66
Accrued interest - current and long term	127	260
Other current and non-current liabilities	19	21
Net cash used in operating activities	(3,688)	(11,044)
Cash Flows from Investing Activities:
Purchases of marketable securities	(3,522)	(2,203)
Proceeds from sale and maturities of marketable securities	3,830	4,336
Acquisition of product rights	0	(2,000)
Additions to property, plant and equipment	(214)	(135)
Proceeds from disposal of property and equipment	14	0
Net cash provided by (used in) by investing activities	108	(2)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	(529)
Proceeds from “at-the-market” offering	225	0
Proceeds from registered direct offering	7,636	0
Offering transaction costs	(611)	0
Principal payments on debt	(1,960)	0
Net cash provided by (used in) financing activities	5,291	(520)
Net increase (decrease) in cash and cash equivalents	1,711	(11,566)
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	2,485	774
Cash paid (refunded) during the year for:
Interest	844	765
Income taxes, net of refunds	$ 0	$ 14

CONSOLIDATED STATEMENTS OF CAS8

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2014USD ($)shares
Stock options
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted	5
Common stock withheld in exercise costs in shares	3
Common stock withheld in exercise costs | $	$ 32
Withholding of exercise cost in shares	1
Minimum statutory withholding payroll taxes withheld | $	$ 4
Common Stock issued upon exercise	1
Restricted Stock Units (RSUs) [Member]
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted	166
Common stock withheld in exercise costs in shares	1
Common stock withheld in exercise costs | $	$ 7
Withholding of exercise cost in shares	63
Minimum statutory withholding payroll taxes withheld | $	$ 525
Common Stock issued upon exercise	102

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2015
Description Of Business Disclosure [Abstract]
DESCRIPTION OF BUSINESS	Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® and Limitx™ Technologies are intended to address methods of product tampering associated with opioid abuse while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine into methamphetamine. Oxaydo® Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first and only approved immediate-release oxycodone product in the United States with abuse deterrent labeling. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. We launched our first Impede Technology product, Nexafed, into the United States market in December 2012 and launched our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC (“Bayer”) entered into a License and Development Agreement (the “Bayer Agreement”) pursuant to which we granted Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine – containing product and providing for the joint development of such product using our Impede Technology for the U.S. market. Our third abuse deterrent technology, Limitx, is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. In January 2016, our Investigational New Drug Application, or IND, filed with the FDA for our lead Limitx oral abuse deterrent drug candidate using the opioid hydromorphone HC1 (“LTX-04”), was allowed to proceed to clinical testing. We have commenced our initial Phase I exploratory pharmacokinetic study of LTX-04. We are also developing an immediate-release hydrocodone bitartrate with acetaminophen product utilizing our Limitx technology. Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split effected by us on August 28, 2015.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions. Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation. Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations. The Company considers cash and cash equivalents to include cash in financial institutions and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature. The Company’s marketable securities at December 31, 2015 and 2014 primarily consist of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established. The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, accrued expenses and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company believes the fair value of long-term debt approximates its carrying value based upon the borrowing rates currently available to the Company for loans with similar terms. As discussed above, marketable securities are recorded at fair value. Credit Risk : Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities. Customers: 10 10 Customer 2015 2014 Rite Aid Corporation 54 % 28 % Cardinal Health, Inc. 14 % 24 % AmerisourceBergen Corporation * 13 % McKesson Corporation * 13 % Kroger Foods * 11 % Accounts receivable from certain of our customers at December 31, 2015 and 2014 accounting for 10 10 Customer 2015 2014 Rite Aid Corporation 68 % 83 % McKesson Corporation 11 % ** Kroger Foods ** 13 % Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed® product line. Inventories at December 31, 2014 consisted of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed® product. During 2014, we purchased raw material and packaging material inventories for $ 260 Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred. Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. Building and improvements 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10 Deferred Debt Issuance Costs and Debt Discount Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method. See Recent Accounting Pronouncements License Fee Revenue In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered on the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering into an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to Acura including an immediate non-refundable payment of $ 500 250 On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology. Egalet paid us $5.0 million upon signing the Egalet Agreement. The payment was non-refundable and non-creditable when made and we had no further requirements to earn the payment. The amount was recognized as revenue when received (see Note 3). Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made and is recognized as revenue when received. In October 2015, Egalet paid us a $ 2.5 Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $ 170 In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $ 5 In connection with our License, Development, and Commercialization Agreement dated October 30, 2007 with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer Inc. (the “Pfizer Agreement”), we began earning royalties on Oxecta starting in February 2013. We recorded royalties of approximately $ 4 Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers. During 2014, we continued deferring the recognition of revenue and at December 31, 2014 we had accumulated deferred revenue of $ 353 314 120 255 205 The Company records the cost of its advertising efforts when services are performed or goods are delivered. The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material. Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We had no impairment charges for the years ended 2015 and 2014. Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $ 0.2 0.1 We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended 2015 2014 Research and development: Stock option awards $ 158 $ 220 RSU awards - - $ 158 $ 220 Selling, general and administrative: Stock option awards 384 550 RSU awards 95 146 $ 479 $ 696 Total share-based compensation expense $ 637 $ 916 Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss). We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2015 and 2014, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 or 2014 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. Years ended December 31, 2015 2014 EPS – basic Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Basic weighted average shares outstanding 10,796 9,779 EPS - basic $ (0.46) $ (1.35) EPS – assuming dilution Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 10,796 9,779 EPS - diluted $ (0.46) $ (1.35) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,198 911 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,258 971 Revenue from Contracts with Customers In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the transition method we will utilize to adopt the standard for use in 2018. Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Presentation of Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-03, "Interest Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs."

LICENSE, DEVELOPMENT, AND COMME

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS	12 Months Ended
	Dec. 31, 2015
Research and Development Disclosure [Abstract]
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT	NOTE 3 – LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS Egalet Agreement On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. Egalet paid us a $ 5.0 2.5 one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period. Bayer Agreement On June 15, 2015, we and Bayer entered into a License and Development Agreement (the “Bayer Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products. We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed Product in countries with patent coverage and a reduced royalty elsewhere. The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time. Terminated Pfizer Agreement In 2007, we entered into License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). In April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return to us of Oxaydo and all Aversion product rights in exchange for a one-time termination payment of $ 2.0 207 155 260

INVESTMENTS IN MARKETABLE SECUR

INVESTMENTS IN MARKETABLE SECURITIES	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS IN MARKETABLE SECURITIES	NOTE 4 – INVESTMENTS IN MARKETABLE SECURITIES December 31, 2015 December 31, 2014 Marketable securities: Corporate bonds — maturing within 1 year $ 3.1 $ 3.5 Corporate bonds — maturing after 1 year and through March 2017 0.4 2.8 Exchange-traded funds 7.3 5.0 Total marketable securities $ 10.8 $ 11.3 The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our marketable securities are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs. December 31, 2015 Cost Gross Gross Fair Value Available-for-sale: Corporate bonds $ 3.6 $ - $ (0.1) $ 3.5 Exchange-traded funds 7.3 - - 7.3 Total - Current $ 10.9 $ - $ (0.1) $ 10.8 December 31, 2014 Cost Gross Gross Fair Value Available-for-sale: Corporate bonds $ 6.3 $ - $ - $ 6.3 Exchange-traded funds 5.0 - - 5.0 Total - Current $ 11.3 $ - $ - $ 11.3 Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted market prices in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable market-based inputs or unobservable inputs that are corroborated by market data. Fair values determined based on Level 3 inputs utilize unobservable inputs reflecting the reporting entity’s own assumptions. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 3.5 - 3.5 - Exchange-traded funds 7.3 7.3 - - Total $ 10.8 $ 7.3 $ 3.5 $ - December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 6.3 - 6.3 - Exchange-traded funds 5.0 5.0 - - Total $ 11.3 $ 5.0 $ 6.3 $ - Accumulated Other Comprehensive Income (Loss) Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at December 31, 2015 and 2014 consisted of unrealized losses on securities of $ 65 13

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 – INVENTORIES Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed product line. Inventories at December 31, 2014 consisted of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on Nexafed product. During 2014, we purchased selected raw and packaging material inventories for $ 260 At December 31, 2014 we had deferred revenue of $ 350 218 314 120 255 Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred. December 31, 2015 2014 Raw and packaging $ - $ 260 Finished goods 346 44 Total inventory 346 304 Less: inventory reserve - finished goods (70) (-) Net inventory $ 276 $ 304 2015 2014 Beginning of year $ - $ 250 Reserve expense - raw and packaging 260 - Reserve expense - finished goods 70 201 330 451 Inventory write-offs - raw and packaging (260) - Inventory write-offs - finished goods - (451) End of year $ 70 $ -

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 6 – PROPERTY, PLANT AND EQUIPMENT December 31, 2015 2014 Building and improvements $ 1,265 $ 1,259 Scientific equipment 598 595 Computer hardware and software 124 252 Machinery and equipment 508 386 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 2,754 2,751 Less: accumulated depreciation (1,741) (1,794) Total property, plant and equipment, net $ 1,013 $ 957 Depreciation expense was approximately $ 0.1

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 7 – ACCRUED EXPENSES December 31, 2015 2014 Professional services $ 171 $ 253 Other fees and services 64 110 Payroll, payroll taxes and benefits 101 94 Clinical and regulatory services 92 83 Marketing, advertising, and promotion 115 - Property taxes 15 15 Franchise taxes 6 13 $ 564 $ 568

DEBT

DEBT	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
DEBT	NOTE 8 – DEBT On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $ 10.0 8.35 13.35 260 December 1, 2018 1.96 60 7.98 400 December 27, 2020 Expected dividend yield 0.0 % Risk-free interest rate 2.4 % Expected volatility 92 % Expected term (years) 7 On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $ 7.98 2.52 33 2.5 5.0 The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 1 795 The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $ 50 100 231 10.16 The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults. Long-term Debt Current Long-term Total Balance at Dec 31, 2014 $ 1,758 $ 8,242 $ 10,000 Principal payments (1,960) - (1,960) Classification 2,522 (2,522) - Balance at Dec 31, 2015 $ 2,320 $ 5,720 $ 8,040 Debt Discount Current Long-term Total Balance at Dec 31, 2014 $ - $ (281) $ (281) Modification of warrants - (33) (33) Amortization expense - 121 121 Balance at Dec 31, 2015 $ - $ (193) $ (193) Deferred Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2014 $ - $ (162) $ (162) Amortization expense - 65 65 Balance at Dec 31, 2015 $ - $ (97) $ (97) Long-term Debt, net at Dec 31, 2015 $ 2,320 $ 5,430 $ 7,750 2015 2014 Interest expense: Term Loan $ 971 $ 1,024 Debt discount 121 119 Debt issue costs 65 69 Total interest expense $ 1,157 $ 1,212 The annual principal payments of the debt at December 31, 2015 are as follows: Annual Year (in thousands) 2016 $ 2,320 2017 2,741 2018 2,979 Total $ 8,040

EQUITY FINANCINGS

EQUITY FINANCINGS	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
EQUITY FINANCING	NOTE 9 – EQUITY FINANCINGS Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we could sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $ 13 54 225 8 217 On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 1.958 1.958 3.90 7.64 Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering 35 7.0

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
COMMON STOCK WARRANTS	NOTE 10 – COMMON STOCK WARRANTS We have outstanding common stock purchase warrants (“warrants”) exercisable for 60 2.52 2.52 10.0 December 31, 2015 2014 Number WAvg Number WAvg Outstanding, beginning 60 $ 7.98 431 $ 15.75 Issued - - - - Exercised - - - - Expired - - (371) 17.00 Modification - (5.46) - - Outstanding, ending 60 $ 2.52 60 $ 7.98

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
EMPLOYEE BENEFIT PLANS	NOTE 11 – EMPLOYEE BENEFIT PLANS 401(k) and Profit-Sharing Plan We have a 401(k) and Profit-Sharing Plan (the “Plan”) for our employees. Employees may elect to make a basic contribution of up to 80 Stock Option Plans We maintain various stock option plans. Years Ended December 31, 2015 2014 Number of Weighted Number of Weighted Outstanding, beginning 911 $ 20.70 747 $ 24.95 Granted 315 2.01 180 2.60 Exercised - - (6) 6.50 Forfeited or expired (28) 26.75 (10) 17.50 Outstanding, ending 1,198 $ 15.67 911 $ 20.70 Options exercisable 814 $ 22.04 695 $ 26.05 Number of Weighted Outstanding at December 31, 2014 216 $ 3.30 Granted 315 2.01 Vested (146) 3.70 Forfeited (1) 2.69 Outstanding at December 31, 2015 384 $ 1.85 We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date. 2015 2014 Expected dividend yield 0.0 % 0.0 % Risk-free interest rates 2.2 % 2.2 % Average expected volatility 89 % 97 % Expected term (years) 10 10 Weighted average grant date fair value $ 1.72 $ 2.30 The intrinsic value of the option awards which were vested and outstanding at December 31, 2015 was less than $ 10 0.7 Information about the cashless stock option exercises during the last two years is as follows: · There were no option awards exercised during 2015. · During 2014, options to purchase 5 3 32 1 2 Restricted Stock Unit Award Plan We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award. Years Ended December 31, 2015 2014 Number of Number of Number of Number of Outstanding, beginning 29 29 166 166 Granted 42 - 29 - Distributed (26) (26) (166) (166) Vested - 42 - 29 Forfeited or expired - - - - Outstanding, ending 45 45 29 29 2005 Restricted Stock Unit Award Plan Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying the aggregate RSU awards of 660 thousand shares, or 165 thousand shares, were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of the years 2011 thru 2014. 102 63 0.5 2014 Restricted Stock Unit Award Plan Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 330 Information about the awards under the 2014 RSU Plan is as follows: · On May 1, 2014, we awarded approximately 7 50 25 stock, for up to 40% 26 · On January 2, 2015, we awarded approximately 10 stock, for up to 40% 25 45 Information about the distribution of shares under the 2014 RSU Plan is as follows: · On January 2, 2015, 26 4 26 19 7 · On January 4, 2016, 1 41 2 42 33 9

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 12 – INCOME TAXES Provision for Income Taxes December 31, 2015 2014 Benefit at U.S. statutory 34% tax rate $ (1,696) $ (4,491) State taxes (benefit), net of federal effect 41 65 Research and development tax credits - (30) Share-based compensation 184 262 Other 11 2 Change in valuation allowance 1,460 4,192 Provision for income taxes $ - $ - Deferred Tax Assets and Valuation Allowance Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $ 52.8 155.2 34 2.0 2016 2035 0.6 2.4 1.2 which expire in the years 2024 through 2034 0.2 which expire in the years 2016 and 2017 December 31, 2015 2014 (in thousands) Deferred tax assets: Estimated future value of NOLs - Federal $ 52,772 $ 51,503 - State 2,050 2,898 Research and development tax credits 1,394 1,398 Share-based compensation 38 45 Other, net 368 151 Total deferred taxes 56,622 55,995 Valuation allowance (56,622) (55,995) Net deferred tax assets $ - $ - Realization of deferred tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. Valuation allowances are placed on deferred tax assets when uncertainty exists on their near term utilization. We make periodic reviews of our valuation allowances and fluctuations can occur. Those fluctuations may be reflected as income tax expenses or benefits in the period they occur. We continue to maintain full valuation allowance against all of our deferred tax assets at December 31, 2015 due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that amounts of our deferred tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and a benefit from income taxes in such period would be recognized. Uncertainty in Income Taxes We adopted FASB’s statement regarding accounting for uncertainty in income taxes which defined the threshold for recognizing the benefits of tax-return positions in the consolidated financial statements as "more-likely-than-not" to be sustained by the taxing authorities. Our adoption of the standard did not result in establishing a contingent tax liability reserve or a corresponding charge to retained earnings. At each of December 31, 2015 and 2014, we had no liability for income tax associated with uncertain tax positions. If in the future we establish a contingent tax liability reserve related to uncertain tax positions, our practice will be to recognize the interest in interest expense and the penalties in other non-operating expense. The Company files federal and state income tax returns and in the normal course of business the Company is subject to examination by these taxing authorities. As of December 31, 2015, the Company’s tax years 2012, 2013 and 2014 are subject to examination by the taxing authorities. With few exceptions, we believe the Company is no longer subject to U.S. federal, state and local examinations by taxing authorities for years before 2012.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 13 – COMMITMENTS AND CONTINGENCIES Purdue Pharma Complaints In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “’007 patent”). The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. In January 2016, the District Court issued a claim construction order in the patent infringement action. The order stated that the term polyvinylpyrrolidone as that term is defined in the claims of the Purdue patent covers all polymeric forms of vinylpyrrolidone, including crospovidone used in Oxaydo. We deny the allegations in the complaint, believe they are without merit and are defending the action vigorously. As is the case with patent litigation, there is a risk that the Court may enjoin the making, using, selling and offering for sale Oxaydo and/or may find that Oxaydo infringes the ‘007 patent. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to this matter as of December 31, 2015. In December 2014, the Company entered into an agreement with Purdue Pharma L.P. to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby the Company conceded Purdue Pharma’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $500 thousand. In June 2015, the Company received an additional $250 thousand payment from Purdue Pharma relating to the December 2014 agreement. Reglan ® /Metoclopramide Litigation Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. In the Pennsylvania action, over 200 lawsuits have been filed against Acura and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs. In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by Acura. We discontinued manufacture and distribution of generic metoclopramide more than 18 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al. In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett Mensing As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of December 31, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier. Paragraph IV ANDA Litigation and License Grants On or about September 17, 2012, the FDA began accepting Abbreviated New Drug Applications, or ANDAs, referencing Oxaydo. To date, we have received Paragraph IV Certification Notices under 21 U.S.C. 355(j) (a Paragraph IV Notice) from five separate generic sponsors of an ANDA for a generic drug listing Oxaydo as the reference listed drug. The Paragraph IV Notices state that each generic sponsor believes that our Aversion Technology patents listed in FDA’s Orange Book are invalid, unenforceable or not infringed. We initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc., and Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book. We dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry. We have entered into distinct Settlement Agreements with each of Par, Impax, Ranbaxy and Sandoz to settle our patent infringement actions. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. Par is entitled to launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxaydo product. Impax and Sandoz are entitled to launch their generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax and Sandoz would become effective prior to such time. In certain circumstances, Sandoz may be required to pay us a royalty on net profits of their generic Oxaydo product. Our Settlement Agreement with Ranbaxy provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product. Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition. Facility Lease The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2017 25 SUPPLEMENTARY DATA (UNAUDITED) For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, Net revenues $ 5,357 $ 341 $ 210 $ 2,679 Operating expenses 3,845 2,739 2,615 3,389 Operating income (loss) 1,512 (2,398) (2,405) (710) Net income (loss) $ 1,239 $ (2,663) $ (2,649) $ (916) Basic income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) Diluted income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, Net revenues $ 42 $ 35 $ 145 $ 529 Operating expenses 3,868 3,307 2,791 2,984 Operating loss (3,826) (3,272) (2,646) (2,455) Net loss $ (4,088) $ (3,521) $ (2,904) $ (2,696) Basic loss per share $ (0.40) $ (0.35) $ (0.30) $ (0.30) Diluted loss per share $ (0.40) $ (0.35) $ (0.30) $ (0.30)

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of our wholly-owned subsidiary, Acura Pharmaceutical Technologies Inc., after elimination of intercompany accounts and transactions.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior years' amounts to conform to the current year's presentation.
Management Estimates	Management Estimates Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Management periodically evaluates estimates used in the preparation of the consolidated financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based on such periodic evaluations.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash and cash equivalents to include cash in financial institutions and money market funds. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Our cash and cash equivalents are governed by our investment policy as approved by our Board of Directors. The carrying amount of cash and cash equivalents approximates its fair value due to its short-term nature.
Marketable Securities	Marketable Securities The Company’s marketable securities at December 31, 2015 and 2014 primarily consist of corporate debt securities and exchange-traded funds. Our marketable securities are governed by our investment policy as approved by our Board of Directors. The Company’s marketable securities are classified as available-for-sale and are recorded at fair value, based upon quoted market prices or net asset value. Unrealized temporary adjustments to fair value are included in a separate component of stockholders’ equity as unrealized gains and losses and reported as a component of accumulated other comprehensive income (loss). No gains or losses on marketable securities are realized until shares are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.
Fair Value of Other Financial Instruments	Fair Value of Other Financial Instruments The Company’s financial instruments consist primarily of cash and cash equivalents, marketable securities, accounts and other receivables, trade accounts payable, accrued expenses and our long-term debt. The carrying amounts of these financial instruments, other than marketable securities and our long-term debt, are representative of their respective fair values due to their relatively short maturities. The Company believes the fair value of long-term debt approximates its carrying value based upon the borrowing rates currently available to the Company for loans with similar terms. As discussed above, marketable securities are recorded at fair value.
Concentration of Credit Risk	Concentration of Credit Risk Credit Risk : Financial instruments that potentially subject the Company to a significant concentration of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. However, management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Additionally, the Company’s excess cash is invested in accordance with the investment policy approved by our Board of Directors that seeks a combination of both liquidity and safety of principal using diversification of investments, through investments such as investment grade corporate debt securities with varying maturities. To date, the Company has not experienced any material realized losses on its cash, cash equivalents, and marketable securities. Customers: 10 10 Customer 2015 2014 Rite Aid Corporation 54 % 28 % Cardinal Health, Inc. 14 % 24 % AmerisourceBergen Corporation * 13 % McKesson Corporation * 13 % Kroger Foods * 11 % Accounts receivable from certain of our customers at December 31, 2015 and 2014 accounting for 10 10 Customer 2015 2014 Rite Aid Corporation 68 % 83 % McKesson Corporation 11 % ** Kroger Foods ** 13 %
Inventories	Inventories Inventories at December 31, 2015 consist of finished goods held for distribution and sale on our Nexafed® product line. Inventories at December 31, 2014 consisted of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed® product. During 2014, we purchased raw material and packaging material inventories for $ 260 Our purchases of active pharmaceutical ingredients and raw materials required for our development and clinical trial manufacture of product candidates utilizing our Aversion®, Impede® or Limitx Technologies are expensed as incurred.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, less accumulated depreciation. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. Building and improvements 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10
Debt Issuance Costs and Debt Discount	Debt Issuance Costs and Debt Discount Deferred debt issuance costs include costs of debt financing undertaken by the Company, including legal fees, placement fees and other direct costs of the financing. Debt discount is the value attributable to warrants issued in conjunction with the financing. Debt issuance costs and debt discount are amortized into interest expense over the term of the related debt using the effective interest method.
License Fees	License Fees In December 2014, the Company entered into an agreement with Purdue Pharma to settle a patent interference action regarding certain intellectual property held by Acura (U.S. Patent No. 8,101,630). The dispute centered upon the issue of which company has priority in developing the invention. The parties agreed to forgo protracted litigation and the uncertainties arising therefrom by entering an agreement whereby Acura conceded Purdue’s claim of priority in exchange for certain financial consideration to us including an immediate non-refundable payment of $ 500 250 On January 7, 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) entered into a Collaboration and License Agreement to commercialize Oxaydo tablets (formerly known as Oxecta) utilizing our Aversion® Technology. Egalet paid us an upfront payment of $5.0 million upon signing the Egalet Agreement
Milestone Revenue
Collaboration Revenue	Collaboration Revenue Collaboration revenue is derived from reimbursement of development expenses, such as under our agreement with Bayer, and are recognized when costs are incurred pursuant to the agreements. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreements. We recognized $ 170
Royalty Revenue	In connection with our Collaboration and License Agreement with Egalet to commercialize Oxaydo tablets we will receive a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year over the term of the agreement (excluding net sales resulting from any co-promotion efforts by us). We recognize royalty revenue each calendar quarter based on net sales reported to us by Egalet in accordance with the agreement. Egalet’s first commercial sale of Oxaydo occurred in October 2015 and we have recorded royalties of $ 5 In connection with our License, Development, and Commercialization Agreement dated October 30, 2007 with King Pharmaceuticals Research and Development, Inc., now a subsidiary of Pfizer Inc. (the “Pfizer Agreement”), we began earning royalties on Oxecta starting in February 2013. We recorded royalties of approximately $ 4 Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer
Product Sales	Product Sales Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers. During 2014, we continued deferring the recognition of revenue and at December 31, 2014 we had accumulated deferred revenue of $ 353 314 120 255 205
Advertising Costs	Advertising Costs The Company records the cost of its advertising efforts when services are performed or goods are delivered.
Shipping and Handling Costs	Shipping and Handling Costs The Company records shipping and handling costs in selling expenses. The amounts recorded from the sales of Nexafed® were not material.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets such as the intangible asset and property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Recoverability of the assets to be held and used is measured by a comparison of the carrying amount of the asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying value of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. We had no impairment charges for the years ended 2015 and 2014.
Research and Development Activities	Research and Development Activities Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. During 2015, we entered into a cancelable arrangement for contract manufacturing services on a project to integrate Impede 2.0 technology into our commercially available Nexafed 30mg tablet while moving supply to an alternate contract manufacturer. Approximately $ 0.2 0.1
Share-based Compensation	We have several share-based compensation plans covering stock options and RSUs for our employees and directors, which are described more fully in Note 11. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost. Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended 2015 2014 Research and development: Stock option awards $ 158 $ 220 RSU awards - - $ 158 $ 220 Selling, general and administrative: Stock option awards 384 550 RSU awards 95 146 $ 479 $ 696 Total share-based compensation expense $ 637 $ 916
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes all changes in equity during a period except those that resulted from investments by or distributions to the Company’s stockholders. Other comprehensive income (loss) refers to revenues, expenses, gains and losses that, under GAAP, are included in comprehensive income (loss), but excluded from net income (loss) as these amounts are recorded directly as an adjustment to stockholders’ equity. The Company’s other comprehensive income (loss) is composed of unrealized gains (losses) on certain holdings of marketable securities, net of any realized gains (losses) included in net income (loss).
Income Taxes	Income Taxes We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and the income tax basis of assets and liabilities and are measured using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At December 31, 2015 and 2014, 100% of all remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.
Earnings Per Share (“EPS”)	Earnings Per Share (“EPS”) Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 11). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 or 2014 as the Company reported a net loss for the years and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. Years ended December 31, 2015 2014 EPS – basic Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Basic weighted average shares outstanding 10,796 9,779 EPS - basic $ (0.46) $ (1.35) EPS – assuming dilution Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 10,796 9,779 EPS - diluted $ (0.46) $ (1.35) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,198 911 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,258 971
Recent Accounting Pronouncements	Revenue from Contracts with Customers In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the transition method we will utilize to adopt the standard for use in 2018. Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “ Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Presentation of Debt Issuance Costs In April 2015, the FASB issued ASU No. 2015-03, "Interest Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs." 162

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Concentration of Risk, by Risk Factor	10 10 Customer 2015 2014 Rite Aid Corporation 54 % 28 % Cardinal Health, Inc. 14 % 24 % AmerisourceBergen Corporation * 13 % McKesson Corporation * 13 % Kroger Foods * 11 % Accounts receivable from certain of our customers at December 31, 2015 and 2014 accounting for 10 10 Customer 2015 2014 Rite Aid Corporation 68 % 83 % McKesson Corporation 11 % ** Kroger Foods ** 13 %
Estimated Lives of Major Classification of Depreciable Assets	The estimated useful lives of the major classification of depreciable assets are: Building and improvements 10 40 Land and improvements 20 40 Machinery and equipment 7 10 Scientific equipment 5 10 Computer hardware and software 3 10
Non-Cash Share-Based Compensation Expense	Our share-based compensation expense recognized in the Company’s results of operations from all types of instruments issued comprised the following (in thousands): Year ended 2015 2014 Research and development: Stock option awards $ 158 $ 220 RSU awards - - $ 158 $ 220 Selling, general and administrative: Stock option awards 384 550 RSU awards 95 146 $ 479 $ 696 Total share-based compensation expense $ 637 $ 916
Computation of Diluted Earnings (loss) Per Share	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands, except per share data): Years ended December 31, 2015 2014 EPS – basic Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Basic weighted average shares outstanding 10,796 9,779 EPS - basic $ (0.46) $ (1.35) EPS – assuming dilution Numerator: net loss $ (4,989) $ (13,209) Denominator (weighted): Common shares 10,777 9,770 Vested RSUs 19 9 Stock options - - Common stock warrants - - Diluted weighted average shares outstanding 10,796 9,779 EPS - diluted $ (0.46) $ (1.35) Excluded dilutive securities: Common stock issuable (non weighted): Stock options 1,198 911 Common stock warrants 60 60 Total excluded potentially dilutive shares 1,258 971

INVESTMENTS IN MARKETABLE SEC24

INVESTMENTS IN MARKETABLE SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Investments in marketable securities consisted of the following (in millions): December 31, 2015 December 31, 2014 Marketable securities: Corporate bonds — maturing within 1 year $ 3.1 $ 3.5 Corporate bonds — maturing after 1 year and through March 2017 0.4 2.8 Exchange-traded funds 7.3 5.0 Total marketable securities $ 10.8 $ 11.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions): December 31, 2015 Cost Gross Gross Fair Value Available-for-sale: Corporate bonds $ 3.6 $ - $ (0.1) $ 3.5 Exchange-traded funds 7.3 - - 7.3 Total - Current $ 10.9 $ - $ (0.1) $ 10.8 December 31, 2014 Cost Gross Gross Fair Value Available-for-sale: Corporate bonds $ 6.3 $ - $ - $ 6.3 Exchange-traded funds 5.0 - - 5.0 Total - Current $ 11.3 $ - $ - $ 11.3
Fair Value, Assets Measured on Recurring Basis	Our assets measured at fair value or disclosed at fair value on a recurring basis as at December 31, 2015 and 2014 consisted of the following (in millions): December 31, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 3.5 - 3.5 - Exchange-traded funds 7.3 7.3 - - Total $ 10.8 $ 7.3 $ 3.5 $ - December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Corporate bonds 6.3 - 6.3 - Exchange-traded funds 5.0 5.0 - - Total $ 11.3 $ 5.0 $ 6.3 $ -

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
Inventories	Inventories are summarized as follows (in thousands): December 31, 2015 2014 Raw and packaging $ - $ 260 Finished goods 346 44 Total inventory 346 304 Less: inventory reserve - finished goods (70) (-) Net inventory $ 276 $ 304
Inventory Reserve	2015 2014 Beginning of year $ - $ 250 Reserve expense - raw and packaging 260 - Reserve expense - finished goods 70 201 330 451 Inventory write-offs - raw and packaging (260) - Inventory write-offs - finished goods - (451) End of year $ 70 $ -

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	Property, plant and equipment are summarized as follows (in thousands): December 31, 2015 2014 Building and improvements $ 1,265 $ 1,259 Scientific equipment 598 595 Computer hardware and software 124 252 Machinery and equipment 508 386 Land and improvements 162 162 Other personal property 70 70 Office equipment 27 27 2,754 2,751 Less: accumulated depreciation (1,741) (1,794) Total property, plant and equipment, net $ 1,013 $ 957

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accurued Expenses	Accrued expenses are summarized as follows (in thousands): December 31, 2015 2014 Professional services $ 171 $ 253 Other fees and services 64 110 Payroll, payroll taxes and benefits 101 94 Clinical and regulatory services 92 83 Marketing, advertising, and promotion 115 - Property taxes 15 15 Franchise taxes 6 13 $ 564 $ 568

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Our debt is summarized below (in thousands): Long-term Debt Current Long-term Total Balance at Dec 31, 2014 $ 1,758 $ 8,242 $ 10,000 Principal payments (1,960) - (1,960) Classification 2,522 (2,522) - Balance at Dec 31, 2015 $ 2,320 $ 5,720 $ 8,040 Debt Discount Current Long-term Total Balance at Dec 31, 2014 $ - $ (281) $ (281) Modification of warrants - (33) (33) Amortization expense - 121 121 Balance at Dec 31, 2015 $ - $ (193) $ (193) Deferred Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2014 $ - $ (162) $ (162) Amortization expense - 65 65 Balance at Dec 31, 2015 $ - $ (97) $ (97) Long-term Debt, net at Dec 31, 2015 $ 2,320 $ 5,430 $ 7,750
Schedule Of Fair Value Of Warrants	The fair value of the warrants was determined using the Black-Scholes option-pricing model. Significant assumptions used in the Black-Scholes model were: Expected dividend yield 0.0 % Risk-free interest rate 2.4 % Expected volatility 92 % Expected term (years) 7
Schedule of Interest Expense	Our interest expense consisted of the following (in thousands): 2015 2014 Interest expense: Term Loan $ 971 $ 1,024 Debt discount 121 119 Debt issue costs 65 69 Total interest expense $ 1,157 $ 1,212
Schedule Of Long Term Debt Future Principal Payments Year	The annual principal payments of the debt at December 31, 2015 are as follows: Annual Year (in thousands) 2016 $ 2,320 2017 2,741 2018 2,979 Total $ 8,040

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Schedule Of Common Stock Warrant Activity	Our warrant activity during the years ended December 31, 2015 and 2014 is shown below (in thousands except price data): December 31, 2015 2014 Number WAvg Number WAvg Outstanding, beginning 60 $ 7.98 431 $ 15.75 Issued - - - - Exercised - - - - Expired - - (371) 17.00 Modification - (5.46) - - Outstanding, ending 60 $ 2.52 60 $ 7.98

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Stock Options, Activity	Years Ended December 31, 2015 2014 Number of Weighted Number of Weighted Outstanding, beginning 911 $ 20.70 747 $ 24.95 Granted 315 2.01 180 2.60 Exercised - - (6) 6.50 Forfeited or expired (28) 26.75 (10) 17.50 Outstanding, ending 1,198 $ 15.67 911 $ 20.70 Options exercisable 814 $ 22.04 695 $ 26.05
Schedule of Nonvested Share Activity	The following table summarizes information about nonvested stock options outstanding at December 31, 2015 (in thousands except per price data): Number of Weighted Outstanding at December 31, 2014 216 $ 3.30 Granted 315 2.01 Vested (146) 3.70 Forfeited (1) 2.69 Outstanding at December 31, 2015 384 $ 1.85
Schedule of fair value of the warrants	The assumptions used in the Black-Scholes model to determine fair value for the 2015 and 2014 stock option grants were: 2015 2014 Expected dividend yield 0.0 % 0.0 % Risk-free interest rates 2.2 % 2.2 % Average expected volatility 89 % 97 % Expected term (years) 10 10 Weighted average grant date fair value $ 1.72 $ 2.30
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of the grants under the RSU Plans as of December 31, 2015 and 2014, and for the years then ended consisted of the following (in thousands): Years Ended December 31, 2015 2014 Number of Number of Number of Number of Outstanding, beginning 29 29 166 166 Granted 42 - 29 - Distributed (26) (26) (166) (166) Vested - 42 - 29 Forfeited or expired - - - - Outstanding, ending 45 45 29 29

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Provision for Income Taxes	The reconciliation between our provision for income taxes and the amounts computed by multiplying our loss before taxes by the U.S. statutory tax rate is as follows (in thousands): December 31, 2015 2014 Benefit at U.S. statutory 34% tax rate $ (1,696) $ (4,491) State taxes (benefit), net of federal effect 41 65 Research and development tax credits - (30) Share-based compensation 184 262 Other 11 2 Change in valuation allowance 1,460 4,192 Provision for income taxes $ - $ -
Components Of Deferred Tax Assets	As of December 31, 2015 we had federal research and development tax credits of approximately $ 1.2 which expire in the years 2024 through 2034 0.2 which expire in the years 2016 and 2017 December 31, 2015 2014 (in thousands) Deferred tax assets: Estimated future value of NOLs - Federal $ 52,772 $ 51,503 - State 2,050 2,898 Research and development tax credits 1,394 1,398 Share-based compensation 38 45 Other, net 368 151 Total deferred taxes 56,622 55,995 Valuation allowance (56,622) (55,995) Net deferred tax assets $ - $ -

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Selected unaudited quarterly consolidated financial data	Selected unaudited quarterly consolidated financial data is shown below (in thousands except per share amounts): For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, Net revenues $ 5,357 $ 341 $ 210 $ 2,679 Operating expenses 3,845 2,739 2,615 3,389 Operating income (loss) 1,512 (2,398) (2,405) (710) Net income (loss) $ 1,239 $ (2,663) $ (2,649) $ (916) Basic income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) Diluted income (loss) per share $ 0.13 $ (0.28) $ (0.23) $ (0.08) For Three Month Periods Ended Mar. 31, June 30, Sept. 30, Dec. 31, Net revenues $ 42 $ 35 $ 145 $ 529 Operating expenses 3,868 3,307 2,791 2,984 Operating loss (3,826) (3,272) (2,646) (2,455) Net loss $ (4,088) $ (3,521) $ (2,904) $ (2,696) Basic loss per share $ (0.40) $ (0.35) $ (0.30) $ (0.30) Diluted loss per share $ (0.40) $ (0.35) $ (0.30) $ (0.30)

SUMMARY OF SIGNIFICANT ACCOUN33

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of Risk by Risk Factor (Detail)	12 Months Ended
	Dec. 31, 2015		Dec. 31, 2014
Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%
Rite Aid Corporation | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	54.00%		28.00%
Rite Aid Corporation | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	68.00%		83.00%
Cardinal Health, Inc. | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	14.00%		24.00%
AmerisourceBergen Corporation | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	[1]	13.00%
McKesson Corporation | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	[1]	13.00%
McKesson Corporation | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	11.00%		0.00%	[2]
Kroger Foods | Sales Revenue, Net
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	[1]	11.00%
Kroger Foods | Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	0.00%	[2]	13.00%
[1]	accounted for less than 10% of our annual product sales.
[2]	accounted for less than 10% of our gross accounts receivable.

SUMMARY OF SIGNIFICANT ACCOUN34

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Estimated Useful Lives of the Major Classification of Depreciable Assets (Detail)	12 Months Ended
	Dec. 31, 2015
Building and Building Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Building and Building Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Land Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Scientific Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Scientific Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computer Hardware and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Hardware and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years

SUMMARY OF SIGNIFICANT ACCOUN35

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Non-Cash Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 637	$ 916
Research and Development Expense
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	158	220
Research and Development Expense | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	158	220
Research and Development Expense | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	0	0
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	479	696
Selling, General and Administrative | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	384	550
Selling, General and Administrative | Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total share-based compensation expense	$ 95	$ 146

SUMMARY OF SIGNIFICANT ACCOUN36

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
EPS - basic
Numerator: net loss	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Denominator (weighted):
Common shares									10,777	9,770
Vested RSUs									19	9
Basic weighted average shares outstanding									10,796	9,779
EPS - basic	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
EPS - assuming dilution
Numerator: net loss	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Denominator (weighted):
Common shares									10,777	9,770
Vested RSUs									19	9
Stock options									0	0
Common stock warrants									0	0
Diluted weighted average shares outstanding									10,796	9,779
EPS - diluted	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,258	971
Common stock warrants [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									60	60
Employee Stock Option [Member]
Common stock issuable (non weighted):
Total excluded potentially dilutive shares									1,198	911

SUMMARY OF SIGNIFICANT ACCOUN37

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Detail) - USD ($) $ in Thousands	Apr. 09, 2014	Oct. 31, 2015	Jun. 30, 2015	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Financing Receivable, Impaired [Line Items]
Deferred Revenue, Revenue Recognized							$ 353
Royalty Revenue, Total						$ 5	4
Other Revenue, Net						170	0
Sales Revenue, Goods, Net, Total				$ 314	$ 314	662	247
Revenue Recognition, Sales Returns, Reserve for Sales Returns				120	120	205
Related Parties Amount in Cost of Sales				$ 255	$ 255
Professional and Contract Services Expense						$ 200	100
New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets							$ 162
Egalet Ltd [Member]
Financing Receivable, Impaired [Line Items]
Loss Contingency, Settlement Agreement, Terms						Egalet paid us an upfront payment of $5.0 million upon signing the Egalet Agreement
Proceeds from Milestone Payment On Agreement		$ 2,500
Sales Revenue, Net [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Sales Revenue, Net [Member] | Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%	10.00%
Accounts Receivable [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%
Accounts Receivable [Member] | Minimum [Member]
Financing Receivable, Impaired [Line Items]
Concentration Risk, Percentage						10.00%	10.00%
Purdue Pharma [Member]
Financing Receivable, Impaired [Line Items]
Litigation Settlement, Expense			$ 250				$ 500
Pfizer [Member]
Financing Receivable, Impaired [Line Items]
Contract Termination Claims, Description	Pfizer Agreement was terminated and the rights to Oxecta were returned to us after making a one-time payment of $2.0 million to Pfizer
Pfizer [Member] | Raw Materials [Member]
Financing Receivable, Impaired [Line Items]
Payments to Suppliers							$ 260

LICENSE, DEVELOPMENT, AND COM38

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 09, 2015	Dec. 31, 2015	Dec. 31, 2014
License Development and Commercialization Agreement [Line Items]
Agreement Termination Notice Description		Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Retail Related Inventory, Total		$ 260
Amortization of Intangible Assets		207	$ 155
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination		$ 2,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Minimum Net Sales Reaching Description		one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Licenses Revenue	$ 5,000
Proceeds from Milestone Payment On Agreement	$ 2,500

INVESTMENTS IN MARKETABLE SEC39

INVESTMENTS IN MARKETABLE SECURITIES - Summary of Investments in Marketable Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Marketable securities:
Corporate bonds - maturing within 1 year	$ 3.1	$ 3.5
Corporate bonds - maturing after 1 year and through March 2017	0.4	2.8
Total marketable securities	10.8	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 7.3	$ 5

INVESTMENTS IN MARKETABLE SEC40

INVESTMENTS IN MARKETABLE SECURITIES - Fair Value and Unrealized Gains (Losses) related to the Company’s Available-For-Sale Securities (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Available-for-sale:
Cost	$ 10.9	$ 11.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(0.1)	0
Fair Value	10.8	11.3
Corporate Bonds
Available-for-sale:
Cost	3.6	6.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(0.1)	0
Fair Value	3.5	6.3
Exchange-traded funds
Available-for-sale:
Cost	7.3	5
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 7.3	$ 5

INVESTMENTS IN MARKETABLE SEC41

INVESTMENTS IN MARKETABLE SECURITIES - Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Assets:
Total marketable securities	$ 10.8	$ 11.3
Corporate bonds
Assets:
Total marketable securities	3.5	6.3
Exchange-traded funds
Assets:
Total marketable securities	7.3	5
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	3.5	6.3
Fair Value, Inputs, Level 1 | Corporate bonds
Assets:
Total marketable securities	3.5	6.3
Fair Value, Inputs, Level 1 | Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 2 | Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 2 | Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	7.3	5
Fair Value, Inputs, Level 3 | Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 | Exchange-traded funds
Assets:
Total marketable securities	$ 7.3	$ 5

INVESTMENTS IN MARKETABLE SEC42

INVESTMENTS IN MARKETABLE SECURITIES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Accumulated Other Comprehensive Income (Loss)
Investment In Marketable Securities [Line Items]
Unrealized losses on securities	$ 65	$ 13

INVENTORIES - Schedule of Inven

INVENTORIES - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Inventory [Line Items]
Raw and packaging	$ 0	$ 260
Finished goods	346	44
Total inventory	346	304
Less: inventory reserve - finished goods	(70)	0	$ (250)
Net inventory	$ 276	$ 304

INVENTORIES - Inventory Reserve

INVENTORIES - Inventory Reserve (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Beginning of year	$ 0	$ 250
Reserve expense - raw and packaging	260	0
Reserve expense - finished goods	70	201
Inventory Reserve Expense	330	451
Inventory write-offs - raw and packaging	(260)	0
Inventory write-offs - finished goods	0	(451)
End of year	$ 70	$ 0

INVENTORIES - Additional Inform

INVENTORIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	$ 0		$ 0	$ 260
Deferred Revenue, Current	0		0	353
Sales Revenue, Goods, Net, Total	314	$ 314	662	247
Revenue Recognition, Sales Returns, Reserve for Sales Returns	120	120	$ 205
Related Parties Amount in Cost of Sales	$ 255	$ 255
Nexafed products [Member]
Inventory [Line Items]
Cost of Goods Sold				218
Deferred Revenue, Current				$ 350

PROPERTY, PLANT AND EQUIPMENT46

PROPERTY, PLANT AND EQUIPMENT (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,754	$ 2,751
Less: accumulated depreciation	(1,741)	(1,794)
Total property, plant and equipment, net	1,013	957
Building and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	1,265	1,259
Scientific equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	598	595
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	124	252
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	508	386
Land and improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	70	70
Office equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 27	$ 27

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation	$ 0.1	$ 0.1

ACCRUED EXPENSES (Detail)

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Line Items]
Professional services	$ 171	$ 253
Other fees and services	64	110
Payroll, payroll taxes and benefits	101	94
Clinical and regulatory services	92	83
Marketing, advertising, and promotion	115	0
Property taxes	15	15
Franchise taxes	6	13
Total	$ 564	$ 568

DEBT - Fair Value of Warrants u

DEBT - Fair Value of Warrants using the Black-Scholes option-pricing model - (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Fair Value Of Warrants [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	2.40%	2.20%
Average expected volatility	92.00%	97.00%
Expected term (years)	7 years	10 years

DEBT - Summary of Debt (Detail)

DEBT - Summary of Debt (Detail) - USD ($) $ in Thousands	Jan. 07, 2015	Dec. 31, 2015
Long-term Debt
Balance at Dec 31, 2014	$ 10,000	$ 10,000
Principal payments		(1,960)
Classification		0
Balance at Dec 31, 2015		8,040
Debt Discount
Balance at Dec 31, 2014	(281)	(281)
Modification of warrants	33	33
Amortization expense		121
Balance at Dec 31, 2015		(193)
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	(162)	(162)
Amortization expense		65
Balance at Dec 31, 2015		(97)
Long-term Debt, net at Dec 31, 2015		7,750
Long-term [Member]
Long-term Debt
Balance at Dec 31, 2014	8,242	8,242
Principal payments		0
Classification		(2,522)
Balance at Dec 31, 2015		5,720
Debt Discount
Balance at Dec 31, 2014	(281)	(281)
Modification of warrants		(33)
Amortization expense		121
Balance at Dec 31, 2015		(193)
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	(162)	(162)
Amortization expense		65
Balance at Dec 31, 2015		(97)
Long-term Debt, net at Dec 31, 2015		5,430
Current [Member]
Long-term Debt
Balance at Dec 31, 2014	1,758	1,758
Principal payments		(1,960)
Classification		2,522
Balance at Dec 31, 2015		2,320
Debt Discount
Balance at Dec 31, 2014	0	0
Modification of warrants		0
Amortization expense		0
Balance at Dec 31, 2015		0
Deferred Debt Issuance Costs
Balance at Dec 31, 2014	$ 0	0
Amortization expense		0
Balance at Dec 31, 2015		0
Long-term Debt, net at Dec 31, 2015		$ 2,320

DEBT - Interest Expense (Detail

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Interest expense:
Term Loan	$ 971	$ 1,024
Debt discount	121	119
Debt issue costs	65	69
Total interest expense	$ 1,157	$ 1,212

DEBT - Long-Term Debt (Detail)

DEBT - Long-Term Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
2,016	$ 2,320
2,017	2,741
2,018	2,979
Total	$ 8,040	$ 10,000

DEBT - Additional Information (

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jan. 07, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount				$ 10,000
Debt instrument, interest rate, stated percentage				8.35%
Debt default long term debt percentage				13.35%
Debt Instrument, Maturity Date		Dec. 1, 2018
Debt instrument, fee amount		$ 50
Debt consulting placement fee		100
Debt related commitment fees and debt issuance costs		231
Debt instrument unamortized discount		$ 193	$ 281
Warrants to purchase common stock		60
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.52
Debt instrument Cash Maintenance	$ 2,500
Repayments of Debt	5,000	$ 1,960	$ 0
Additions To Debt Instrument Unamortized Discount	$ 33	33
Debt Instrument, Periodic Payment		260
Debt instrument, periodic payment, principal		$ 1,960
Debt Instrument, Interest Rate, Effective Percentage		10.16%
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98	$ 7.98
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52	$ 2.52
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount		$ 400
Warrants to purchase common stock		60
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.98
Warrants, expiry date		December 27, 2020
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid		$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage		1.00%

EQUITY FINANCINGS - Additional

EQUITY FINANCINGS - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Apr. 18, 2013	Jun. 30, 2015	Dec. 31, 2015
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 13,000
Sale leaseback transaction, transaction costs, financing activities			$ 8
Sale leaseback transaction, net proceeds, financing activities			$ 217
Placement agency reimbursed for expenses		$ 496
Common Stock, Par or Stated Value Per Share			$ 0.01
Common Stock [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock			$ 225
Stock issued during period, shares, new issues			54
Placement Agency Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 0.01
Proceeds from issuance of private placement		$ 7,000
Description for repayment of placement agent		paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses		$ 35
Common Stock, Par or Stated Value Per Share		$ 1
Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 3.90
Proceeds from issuance of private placement		$ 7,640

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Number of Options
Number of Options Outstanding, beginning	60	431
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	(371)
Number of Options Outstanding, ending	60	60
Number of Options, Modification	0	0
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 7.98	$ 15.75
Issued	0	0
Exercised	0	0
Expired	0	17
Modification	(5.46)	0
Weighted Average Exercise Price, ending	$ 2.52	$ 7.98

COMMON STOCK WARRANTS - Additio

COMMON STOCK WARRANTS - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Secured Debt		$ 10
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Common stock Warrant expiration date	December 27, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.98

EMPLOYEE BENEFIT PLANS - Stock

EMPLOYEE BENEFIT PLANS - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	911	747
Number of Options, Granted	315	180
Number of Options, Exercised	0	(6)
Number of Options, Forfeited or expired	(28)	(10)
Number of Options Outstanding, ending	1,198	911
Number of Options exercisable	814	695
Weighted Average Exercise Price, beginning	$ 20.70	$ 24.95
Weighted Average Exercise Price, Granted	2.01	2.60
Weighted Average Exercise Price, Exercised	0	6.50
Weighted Average Exercise Price, Forfeited or expired	26.75	17.50
Weighted Average Exercise Price, ending	15.67	20.70
Weighted Average Exercise Price, Options exercisable	$ 22.04	$ 26.05

EMPLOYEE BENEFIT PLANS - Summar

EMPLOYEE BENEFIT PLANS - Summary of Information about Non Vested Stock Options (Detail) shares in Thousands	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning | shares	216
Granted | shares	315
Vested | shares	(146)
Forfeited | shares	(1)
Outstanding, ending | shares	384
Outstanding beginning, Weighted Average Fair Value | $ / shares	$ 3.30
Granted, Weighted Average Fair Value | $ / shares	2.01
Vested, Weighted Average Fair Value | $ / shares	3.70
Forfeited, Weighted Average Fair Value | $ / shares	2.69
Outstanding ending, Weighted Average Fair Value | $ / shares	$ 1.85

EMPLOYEE BENEFIT PLANS - Assump

EMPLOYEE BENEFIT PLANS - Assumptions Used in Black-Scholes Model to Determine Fair Value for Stock Option Awards Granted (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Risk-free interest rates	2.40%	2.20%
Average expected volatility	92.00%	97.00%
Expected term (years)	7 years	10 years
Weighted average grant date fair value	$ 1.72	$ 2.30

EMPLOYEE BENEFIT PLANS - Summ60

EMPLOYEE BENEFIT PLANS - Summary of RSU Plan (Detail) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	216
Granted	315
Vested	146
Forfeited or expired	1
Outstanding, ending	384	216
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	42	29
Distributed	(26)	(166)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	45	29
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	0	0
Distributed	(26)	(166)
Vested	42	29
Forfeited or expired	0	0
Outstanding, ending	45	29

EMPLOYEE BENEFIT PLANS - Additi

EMPLOYEE BENEFIT PLANS - Additional Information (Detail) - USD ($)

1 Months Ended

8 Months Ended

12 Months Ended

20 Months Ended

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Jan. 02, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

May. 01, 2014

Jan. 31, 2014

Jan. 02, 2015

Jan. 04, 2016

Dec. 31, 2015

Dec. 31, 2014

Jan. 04, 2016

Employee Benefit Plans Disclosure [Line Items]

Aggregate intrinsic value of the option awards vested

$ 6,000

$ 0

$ 6,000

$ 0

Unrecognized compensation cost on unvested option awards outstanding

711,000

$ 711,000

Common stock exercised in cashless exercise features

5,000

Withholding tax obligations

$ 32,000

Statutory Minimum Payroll Taxes

$ 1,000

Number Of Shares Issued On Cashless Exercises

2,000

Number of vested shares distributed to holders

146,000

Common stock exercised in cashless exercise features withheld minimum payroll taxes

3,000

401(k) and Profit-Sharing Plan

Employee Benefit Plans Disclosure [Line Items]

Maximum basic contribution percentage per employee on annual earnings

80.00%

2005 Restricted Stock Unit Award Plan [Member]

Employee Benefit Plans Disclosure [Line Items]

Shares withheld upon elections made to exchange RSUs

63

Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations

$ 525

Number of vested shares distributed to holders

102

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

166,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

one-fourth of vested shares of common stock underlying the aggregate RSU awards of 660 thousand shares, or 166 thousand shares, were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of the years 2011 thru 2014.

2014 Restricted Stock Unit Award Plan [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant

400,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

26,000

Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution

4,000

Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award

330,000

Deferred Compensation Arrangement with Individual, Recorded Liability

$ 45,000

$ 45,000

2014 Restricted Stock Unit Award Plan [Member] | Settled In Cash [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

7,000

2014 Restricted Stock Unit Award Plan [Member] | Distributed In Common Stock [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

26,000

2014 Restricted Stock Unit Award Plan [Member] | Convertible Common Stock [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

19,000

2014 Restricted Stock Unit Award Plan [Member] | Four Non Employee Directors [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

7,000

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

25.00%

25.00%

25.00%

25.00%

25.00%

50.00%

Share-based Compensation Arrangement by Share-based Payment Award, Description

stock, for up to 40%

stock, for up to 40%

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 26,000

2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

41,000

1

Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution

2

2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Settled In Cash [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

9

2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Distributed In Common Stock [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

42

2014 Restricted Stock Unit Award Plan [Member] | Subsequent Event [Member] | Convertible Common Stock [Member]

Employee Benefit Plans Disclosure [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

33

INCOME TAXES - Provision for In

INCOME TAXES - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Provision For Income Taxes [Line Items]
Benefit at U.S. statutory 34% tax rate	$ (1,696)	$ (4,491)
State taxes (benefit), net of federal effect	41	65
Research and development tax credits	0	(30)
Share-based compensation	184	262
Other	11	2
Change in valuation allowance	1,460	4,192
Provision for income taxes	$ 0	$ 0

INCOME TAXES - Components of Ou

INCOME TAXES - Components of Our Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
- Federal	$ 52,772	$ 51,503
- State	2,050	2,898
Research and development tax credits	1,394	1,398
Share-based compensation	38	45
Other, net	368	151
Total deferred taxes	56,622	55,995
Valuation allowance	(56,622)	(55,995)
Net deferred tax assets	$ 0	$ 0

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 52,800
Federal NOLs	$ 155,200
U.S. statutory tax rate	34.00%
Research and development tax credits	$ 1,394	$ 1,398
State income tax benefits	2,000
Valuation allowance, deferred tax asset, change in amount	600	$ 2,400
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 1,200
Research and development expiration period	which expire in the years 2024 through 2034
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits	$ 200
Research and development expiration period	which expire in the years 2016 and 2017
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year	2,035
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year	2,016

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Shedule Of Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Quarterly Financial Information [Line Items]
Net revenues	$ 2,679	$ 210	$ 341	$ 5,357	$ 529	$ 145	$ 35	$ 42	$ 8,587	$ 751
Operating expenses	3,389	2,615	2,739	3,845	2,984	2,791	3,307	3,868	12,588	12,950
Operating income (loss)	(710)	(2,405)	(2,398)	1,512	(2,455)	(2,646)	(3,272)	(3,826)	(4,001)	(12,199)
Net income (loss)	$ (916)	$ (2,649)	$ (2,663)	$ 1,239	$ (2,696)	$ (2,904)	$ (3,521)	$ (4,088)	$ (4,989)	$ (13,209)
Basic income (loss) per share (in dollars per share)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)
Diluted income (loss) per share (in dollars per share)	$ (0.08)	$ (0.23)	$ (0.28)	$ 0.13	$ (0.30)	$ (0.30)	$ (0.35)	$ (0.40)	$ (0.46)	$ (1.35)

COMMITMENTS AND CONTINGENCIES66

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Purdue Pharma [Member]
Commitments and Contingencies Disclosure [Line Items]
Litigation Settlement, Expense	$ 250,000		$ 500,000
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed		150
Number of lawsuits served		50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint		445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space		$ 25,000
Lease expiring date		March 31, 2017